Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-21 4:11 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.100% |
0 (Unchanged) |
Filing History |
| 2024-02-14 7:45 pm Sale |
2023-12-31 | 13G | ALX Oncology Holdings Inc. ALXO |
ORBIMED ADVISORS LLC | 2,255,000 4.500% |
-11,000 (-0.49%) |
Filing History |
| 2024-02-14 7:41 pm Purchase |
2023-12-31 | 13G | InspireMD, Inc. NSPR |
ORBIMED ADVISORS LLC | 2,133,405 9.900% |
2,133,405 (New Position) |
Filing History |
| 2024-02-14 7:36 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 383,148 6.700% |
38,860 (+11.29%) |
Filing History |
| 2024-02-14 7:31 pm Purchase |
2023-12-31 | 13G | Verastem, Inc. VSTM |
ORBIMED ADVISORS LLC | 1,529,115 6.100% |
1,529,115 (New Position) |
Filing History |
| 2024-02-14 7:28 pm Sale |
2023-12-31 | 13G | SI-BONE, Inc. SIBN |
ORBIMED ADVISORS LLC | 2,144,631 5.300% |
-1,056,469 (-33.00%) |
Filing History |
| 2024-02-14 7:21 pm Purchase |
2023-12-31 | 13G | Scholar Rock Holding Corporation SRRK |
ORBIMED ADVISORS LLC | 2,960,000 4.100% |
2,960,000 (New Position) |
Filing History |
| 2024-02-14 7:11 pm Sale |
2023-12-31 | 13G | Protara Therapeutics, Inc. TARA |
ORBIMED ADVISORS LLC | 0 0.000% |
-671,741 (Position Closed) |
Filing History |
| 2024-02-14 7:00 pm Sale |
2023-12-31 | 13G | NeuroPace, Inc. NPCE |
ORBIMED ADVISORS LLC | 4,003,967 15.200% |
-8,314 (-0.21%) |
Filing History |
| 2024-02-14 6:55 pm Sale |
2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
ORBIMED ADVISORS LLC | 0 0.000% |
-7,082,837 (Position Closed) |
Filing History |
| 2024-02-14 6:51 pm Sale |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 0 0.000% |
-10,378,591 (Position Closed) |
Filing History |
| 2024-02-14 6:47 pm Sale |
2023-12-31 | 13G | Kezar Life Sciences, Inc. KZR |
ORBIMED ADVISORS LLC | 192,700 2.700% |
-156,812 (-44.87%) |
Filing History |
| 2024-02-14 6:42 pm Purchase |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
ORBIMED ADVISORS LLC | 3,000,000 6.800% |
3,000,000 (New Position) |
Filing History |
| 2024-02-14 6:36 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 1,667,360 2.500% |
-1,529,516 (-47.84%) |
Filing History |
| 2024-02-14 6:30 pm Sale |
2023-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 0 0.000% |
-7,300,921 (Position Closed) |
Filing History |
| 2024-02-05 4:48 pm Unchanged |
2024-02-05 | 13D | CalciMedica, Inc. CALC |
ORBIMED ADVISORS LLC | 297,380 2.900% |
0 (Unchanged) |
Filing History |
| 2024-02-05 4:42 pm Purchase |
2024-01-30 | 13D | ArriVent BioPharma, Inc. Common Stock AVBP |
ORBIMED ADVISORS LLC | 3,027,328 9.100% |
3,027,328 (New Position) |
Filing History |
| 2024-01-29 4:55 pm Purchase |
2024-01-25 | 13D | Adicet Bio, Inc. ACET |
ORBIMED ADVISORS LLC | 9,772,598 12.900% |
3,125,000 (+47.01%) |
Filing History |
| 2024-01-25 4:25 pm Purchase |
2024-01-23 | 13D | Edgewise Therapeutics, Inc. EWTX |
ORBIMED ADVISORS LLC | 14,756,096 17.300% |
454,545 (+3.18%) |
Filing History |
| 2023-12-29 4:16 pm Sale |
2023-12-28 | 13D | Alpine Immune Sciences, Inc. ALPN |
ORBIMED ADVISORS LLC | 2,680,496 4.600% |
-1,546,347 (-36.58%) |
Filing History |